|
Video: What is a Stock Split?
|
|
Pieris Pharmaceuticals is a biotechnology company that discovers and develops Anticalin-based drugs to target validated disease pathways. Co.'s clinical pipeline includes elarekibep an inhaled IL-4Ra antagonist Anticalin protein to treat uncontrolled asthma, PRS-220, an inhaled CTGF antagonist to treat IPF and other forms for fibrotic lung disease, an immuno-oncology (IO) bispecific PRS-344/S095012 targeting PD-L1 and 4-1BB. Co. has intellectual property rights directed to various aspects of its Anticalin technology platform, allowing for the development and improvement of both its platform and drug candidates. Co.'s development plans focus on its clinical and preclinical programs. According to our PIRS split history records, Pieris Pharmaceuticals has had 1 split. | |
|
Pieris Pharmaceuticals (PIRS) has 1 split in our PIRS split history database. The split for PIRS took place on April 23, 2024. This was a 1 for 80 reverse split, meaning for each 80 shares of PIRS owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 12.5 share position following the split.
When a company such as Pieris Pharmaceuticals conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the PIRS split history from start to finish, an original position size of 1000 shares would have turned into 12.5 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Pieris Pharmaceuticals shares, starting with a $10,000 purchase of PIRS, presented on a split-history-adjusted basis factoring in the complete PIRS split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
04/14/2015 |
|
End date: |
05/03/2024 |
|
Start price/share: |
$280.00 |
|
End price/share: |
$11.08 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-96.04% |
|
Average Annual Total Return: |
-29.99% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$395.46 |
|
Years: |
9.06 |
|
|
|
Date |
Ratio |
04/23/2024 | 1 for 80 |
|
|